AUTHOR=Doshi Gurjyot K. , Li Haojie , Burcu Mehmet , Annavarapu Srinivas , Wells Karen , Imai Kentaro , Moreno Blanca Homet , Singhal Puneet , Mamtani Ronac 

TITLE=Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1210208

DOI=10.3389/fonc.2023.1210208

ISSN=2234-943X

ABSTRACT=<sec><title>Introduction</title><p>Metastatic urothelial carcinoma (mUC) has poor prognosis. A high unmet need exists for novel treatment for those who are unfit for platinum-based chemotherapy.</p></sec><sec><title>Methods</title><p>We aimed to describe real-world temporal changes in patient characteristics and 1L treatment selection for mUC patients in the United States following the approval of anti-PD-1/L1 treatments.  This study was a retrospective, observational study using anonymized and structured oncology electronic medical record (EMR) data from IQVIA and the US Oncology Network iKnowMed (USON).</p></sec><sec><title>Results</title><p>After approval of 1L anti-PD-1/L1 treatment for mUC, there is a marked increase in the use of 1L anti-PD-1/L1 monotherapies, accompanied by a proportional decrease in 1L platinum-based treatments and non-guideline-based therapy; particularly among the elderly (&gt; 75 years) and those with poor ECOG performance status (ECOG PS 2+).</p></sec><sec><title>Discussion</title><p>Anti-PD-1/L1 monotherapies fulfill the prior unmet need of frail mUC patients who are ineligible for platinum-based therapies.</p></sec>